A safety study of inactivated Enterovirus 71 vaccine

References

• Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974; 129:304 - 9; http://dx.doi.org/10.1093/infdis/129.3.304; PMID: 4361245
   PubMed Web of Science ®Google Scholar
• Brown BA, Oberste MS, Alexander JP Jr., Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 1999; 73:9969 - 75; PMID: 10559310
   PubMed Web of Science ®Google Scholar
• Chang LY, Hsia SH, Wu CT, Huang YC, Lin KL, Fang TY, et al. Outcome of enterovirus 71 infections with or without stage-based management: 1998 to 2002. Pediatr Infect Dis J 2004; 23:327 - 32; http://dx.doi.org/10.1097/00006454-200404000-00010; PMID: 15071287
   PubMed Web of Science ®Google Scholar
• Chang LY, Huang LM, Gau SS, Wu YY, Hsia SH, Fan TY, et al. Neurodevelopment and cognition in children after enterovirus 71 infection. N Engl J Med 2007; 356:1226 - 34; http://dx.doi.org/10.1056/NEJMoa065954; PMID: 17377160
   PubMed Web of Science ®Google Scholar
• Ishimaru Y, Nakano S, Yamaoka K, Takami S. Outbreaks of hand, foot, and mouth disease by enterovirus 71. High incidence of complication disorders of central nervous system. Arch Dis Child 1980; 55:583 - 8; http://dx.doi.org/10.1136/adc.55.8.583; PMID: 6254449
   PubMed Web of Science ®Google Scholar
• Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10:778 - 90; http://dx.doi.org/10.1016/S1473-3099(10)70194-8; PMID: 20961813
   PubMed Web of Science ®Google Scholar
• Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, et al, Taiwan Enterovirus Epidemic Working Group. An epidemic of enterovirus 71 infection in Taiwan. N Engl J Med 1999; 341:929 - 35; http://dx.doi.org/10.1056/NEJM199909233411301; PMID: 10498487
   PubMed Web of Science ®Google Scholar
• Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA, Centers for Disease Control and Prevention. Enterovirus surveillance--United States, 1970-2005. MMWR Surveill Summ 2006; 55:1 - 20; PMID: 16971890
   PubMedGoogle Scholar
• Zhang Y, Zhu Z, Yang W, Ren J, Tan X, Wang Y, et al. An emerging recombinant human enterovirus 71 responsible for the 2008 outbreak of hand foot and mouth disease in Fuyang city of China. Virol J 2010; 7:94; http://dx.doi.org/10.1186/1743-422X-7-94; PMID: 20459851
   PubMed Web of Science ®Google Scholar
• Schuffenecker I, Mirand A, Antona D, Henquell C, Chomel JJ, Archimbaud C, et al. Epidemiology of human enterovirus 71 infections in France, 2000-2009. J Clin Virol 2011; 50:50 - 6; http://dx.doi.org/10.1016/j.jcv.2010.09.019; PMID: 21035387
   PubMed Web of Science ®Google Scholar
• McMinn P, Stratov I, Nagarajan L, Davis S. Neurological manifestations of enterovirus 71 infection in children during an outbreak of hand, foot, and mouth disease in Western Australia. Clin Infect Dis 2001; 32:236 - 42; http://dx.doi.org/10.1086/318454; PMID: 11170913
   PubMed Web of Science ®Google Scholar
• Ooi MH, Wong SC, Podin Y, Akin W, del Sel S, Mohan A, et al. Human enterovirus 71 disease in Sarawak, Malaysia: a prospective clinical, virological, and molecular epidemiological study. Clin Infect Dis 2007; 44:646 - 56; http://dx.doi.org/10.1086/511073; PMID: 17278054
   PubMed Web of Science ®Google Scholar
• Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, et al. Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 2011; 29:6269 - 75; http://dx.doi.org/10.1016/j.vaccine.2011.06.044; PMID: 21722686
   PubMed Web of Science ®Google Scholar
• Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, et al. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 2012; 30:3295 - 303; http://dx.doi.org/10.1016/j.vaccine.2012.03.010; PMID: 22426327
   PubMed Web of Science ®Google Scholar
• Meng FY, Li JX, Li XL, Chu K, Zhang YT, Ji H, et al. Tolerability and immunogenicity of an inactivated enterovirus 71 vaccine in Chinese healthy adults and children: an open label, phase 1 clinical trial. Hum Vaccin Immunother 2012; 8:668 - 74; http://dx.doi.org/10.4161/hv.19521; PMID: 22634437
   PubMed Web of Science ®Google Scholar
• Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001; 20:895 - 904; http://dx.doi.org/10.1016/S0264-410X(01)00385-1; PMID: 11738755
   PubMed Web of Science ®Google Scholar
• Wu TC, Wang YF, Lee YP, Wang JR, Liu CC, Wang SM, et al. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice. J Virol 2007; 81:10310 - 5; http://dx.doi.org/10.1128/JVI.00372-07; PMID: 17626076
   PubMed Web of Science ®Google Scholar
• Tung WS, Bakar SA, Sekawi Z, Rosli R. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther 2007; 5:6; http://dx.doi.org/10.1186/1479-0556-5-6; PMID: 17445254
   PubMedGoogle Scholar
• Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008; 26:1855 - 62; http://dx.doi.org/10.1016/j.vaccine.2008.01.058; PMID: 18329759
   PubMed Web of Science ®Google Scholar
• Forster R. Study designs for the nonclinical safety testing of new vaccine products. J Pharmacol Toxicol Methods 2012; 66:1 - 7; http://dx.doi.org/10.1016/j.vascn.2012.04.003; PMID: 22561062
   PubMed Web of Science ®Google Scholar
• Sun Y, Gruber M, Matsumoto M. Overview of global regulatory toxicology requirements for vaccines and adjuvants. J Pharmacol Toxicol Methods 2012; 65:49 - 57; http://dx.doi.org/10.1016/j.vascn.2012.01.002; PMID: 22326278
   PubMed Web of Science ®Google Scholar
• Wolf JJ, Kaplanski CV, Lebron JA. Nonclinical safety assessment of vaccines and adjuvants. Methods Mol Biol 2010; 626:29 - 40; http://dx.doi.org/10.1007/978-1-60761-585-9_3; PMID: 20099119
   PubMedGoogle Scholar
• Huo Y, Li B, Zhang Y, Wang S, Bao M, Gao X, et al. Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein. Regul Toxicol Pharmacol 2007; 49:63 - 74; http://dx.doi.org/10.1016/j.yrtph.2007.05.005; PMID: 17600604
   PubMed Web of Science ®Google Scholar
• Koszalka GW, Johnson NW, Good SS, Boyd L, Chamberlain SC, Townsend LB, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 2002; 46:2373 - 80; http://dx.doi.org/10.1128/AAC.46.8.2373-2380.2002; PMID: 12121907
   PubMed Web of Science ®Google Scholar
• Ryffel B, Weber M. Preclinical safety studies with recombinant human interleukin 6 (rhIL-6) in the primate Callithrix jacchus (marmoset): comparison with studies in rats. J Appl Toxicol 1995; 15:19 - 26; http://dx.doi.org/10.1002/jat.2550150106; PMID: 7538156
   PubMedGoogle Scholar
• Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, et al. Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 2011; 29:4362 - 72; http://dx.doi.org/10.1016/j.vaccine.2011.04.010; PMID: 21501643
   PubMed Web of Science ®Google Scholar
• Keith LS, Jones DE, Chou CH. Aluminum toxicokinetics regarding infant diet and vaccinations. Vaccine 2002; 20:Suppl 3 S13 - 7; http://dx.doi.org/10.1016/S0264-410X(02)00165-2; PMID: 12184359
   PubMed Web of Science ®Google Scholar
• Exley C, Burgess E, Day JP, Jeffery EH, Melethil S, Yokel RA. Aluminum toxicokinetics. J Toxicol Environ Health 1996; 48:569 - 84; http://dx.doi.org/10.1080/009841096161078; PMID: 8772799
   PubMed Web of Science ®Google Scholar
• Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine 2002; 20:Suppl 3 S7 - 12; http://dx.doi.org/10.1016/S0264-410X(02)00164-0; PMID: 12184369
   PubMed Web of Science ®Google Scholar
• Romero Méndez IZ, Shi Y, HogenEsch H, Hem SL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine 2007; 25:825 - 33; http://dx.doi.org/10.1016/j.vaccine.2006.09.039; PMID: 17014935
   PubMed Web of Science ®Google Scholar
• Eickhoff TC, Myers M. Workshop summary. Aluminum in vaccines. Vaccine 2002; 20:Suppl 3 S1 - 4; http://dx.doi.org/10.1016/S0264-410X(02)00163-9; PMID: 12184358
   PubMed Web of Science ®Google Scholar
• Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, Keenlyside RA, Ziegler DW, Retailliau HF, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol 1979; 110:105 - 23; PMID: 463869
   PubMed Web of Science ®Google Scholar
• Verdier F, Patriarca C, Descotes J. Autoantibodies in conventional toxicity testing. Toxicology 1997; 119:51 - 8; http://dx.doi.org/10.1016/S0300-483X(96)03596-2; PMID: 9129195
   PubMed Web of Science ®Google Scholar
• Descotes J. Autoimmunity and toxicity testing. Toxicol Lett 2000; 112-113:461 - 5; http://dx.doi.org/10.1016/S0378-4274(99)00234-9; PMID: 10720766
   PubMed Web of Science ®Google Scholar
• Asturias EJ, Dueger EL, Omer SB, Melville A, Nates SV, Laassri M, et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis 2007; 196:692 - 8; http://dx.doi.org/10.1086/520546; PMID: 17674310
   PubMed Web of Science ®Google Scholar
• Bonnet MC, Dutta A. World wide experience with inactivated poliovirus vaccine. Vaccine 2008; 26:4978 - 83; http://dx.doi.org/10.1016/j.vaccine.2008.07.026; PMID: 18680777
   PubMed Web of Science ®Google Scholar
• Chang LY, King CC, Hsu KH, Ning HC, Tsao KC, Li CC, et al. Risk factors of enterovirus 71 infection and associated hand, foot, and mouth disease/herpangina in children during an epidemic in Taiwan. Pediatrics 2002; 109:e88; http://dx.doi.org/10.1542/peds.109.6.e88; PMID: 12042582
   PubMed Web of Science ®Google Scholar
• Guan D, van der Sanden S, Zeng H, Li W, Zheng H, Ma C, et al. Population dynamics and genetic diversity of C4 strains of human enterovirus 71 in Mainland China, 1998-2010. PLoS One 2012; 7:e44386; http://dx.doi.org/10.1371/journal.pone.0044386; PMID: 22984501
   PubMedGoogle Scholar
• Zhang Y, Tan XJ, Wang HY, Yan DM, Zhu SL, Wang DY, et al. An outbreak of hand, foot, and mouth disease associated with subgenotype C4 of human enterovirus 71 in Shandong, China. J Clin Virol 2009; 44:262 - 7; http://dx.doi.org/10.1016/j.jcv.2009.02.002; PMID: 19269888
   PubMed Web of Science ®Google Scholar
• Mao Q, Li N, Yu X, Yao X, Li F, Lu F, et al. Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71. Arch Virol 2012; 157:37 - 41; http://dx.doi.org/10.1007/s00705-011-1136-3; PMID: 21984267
   PubMed Web of Science ®Google Scholar
• Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, et al. Establishing China’s national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011; 29:9668 - 74; http://dx.doi.org/10.1016/j.vaccine.2011.10.018; PMID: 22015395
   PubMed Web of Science ®Google Scholar
• World Health Organization Expert Committee on Biological Standardization. Guidelines on Nonclinical Evaluation of Vaccines. Geneva, Switzerland 17-21 November 2003. Available at: http://www.who.int/biologicals/publications/nonclinical_evaluation_vaccines_nov_2003.pdf [Last accessed March 1st, 2013]
   Google Scholar